Mumbai, Aug 28 (UNI) Leading mid-sized Pharma Company Marksans Pharmaceutical Limited today announced the acquisition of Relonchem Limited, a leading UK based generic pharmaceutical company, for an undisclosed sum.
Relonchem Limited has clocked sales of about USD 32 million and adjusted EBITDA of USD 5 million in the FY 2007. The acquisition will give Marksans Pharma an immediate sales and marketing front-end access to the highly regulated and lucrative generic medicines market in UK and Europe, the company said in a release here. It expected to derive significant cost benefits by transferring Relonchem Limited's manufacturing operations to its state-of-the-art India manufacturing facilities.
The release said at a macro level, this is another important step by the Company in creating a complete value chain of self-sufficient business models for itself. While building state-of-the-art, regulatory compliant manufacturing and R&D facilities in India that enjoy cost efficiencies, the Company is also creating front-end marketing and distributor network for sales across the world. Thus, reduced costs and a self-owned network of front-end distribution, marketing and sales capabilities will lead to higher margins and profits, while adding significant value to the healthcare systems across the globe.
UNI VK SR